Orchestra BioMed’s $110 Million Series D Financing

Paul Hastings LLP advised Orchestra BioMed on the deal.

Orchestra BioMed, a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced the closing of a $110 million Series D financing. The Series D financing includes investments by Medtronic, funds managed by RTW Investments, Perceptive Advisors, Terumo Corporation, SternAegis Ventures, and other investors.

The Paul Hastings team was led by M&A/Emerging Growth Companies partner Sam Waxman (Picture), and included partners Yariv Katz, Lucas Rachuba, and Todd Schneider; of counsels Keith Pisani and Amy Lawrence; and associates Jordan Goldman, Vinnie Buehler, Anna Hardcastle, Tianzi Wu, Nicolette Ursini and Shai Marshall.

Involved fees earner: Vinnie Buehler – Paul Hastings LLP; Jordan Goldman – Paul Hastings LLP; Anna Hardcastle – Paul Hastings LLP; Yariv Katz – Paul Hastings LLP; Amy Lawrence – Paul Hastings LLP; Shai Marshall – Paul Hastings LLP; Keith Pisani – Paul Hastings LLP; Lucas Rachuba – Paul Hastings LLP; Todd Schneider – Paul Hastings LLP; Nicolette Ursini – Paul Hastings LLP; Samuel Waxman – Paul Hastings LLP; Tianzi Wu – Paul Hastings LLP;

Law Firms: Paul Hastings LLP;

Clients: Orchestra BioMed;

Martina Bellini

Author: Martina Bellini